HomeCompareASDZF vs JNJ

ASDZF vs JNJ: Dividend Comparison 2026

ASDZF yields 20000.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ASDZF wins by $52481917574412746752.00M in total portfolio value
10 years
ASDZF
ASDZF
● Live price
20000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52481917574412746752.00M
Annual income
$51,970,745,957,167,775,000,000,000.00
Full ASDZF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — ASDZF vs JNJ

📍 ASDZF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodASDZFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ASDZF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ASDZF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ASDZF
Annual income on $10K today (after 15% tax)
$1,700,000.00/yr
After 10yr DRIP, annual income (after tax)
$44,175,134,063,592,610,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, ASDZF beats the other by $44,175,134,063,592,610,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ASDZF + JNJ for your $10,000?

ASDZF: 50%JNJ: 50%
100% JNJ50/50100% ASDZF
Portfolio after 10yr
$26240958787206373376.00M
Annual income
$25,985,372,978,583,888,000,000,000.00/yr
Blended yield
99.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ASDZF
No analyst data
Altman Z
-9.7
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ASDZF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricASDZFJNJ
Forward yield20000.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$52481917574412746752.00M$30.3K
Annual income after 10y$51,970,745,957,167,775,000,000,000.00$4,689.40
Total dividends collected$52448189483771600896.00M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ASDZF vs JNJ ($10,000, DRIP)

YearASDZF PortfolioASDZF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$2,010,700$2,000,000.00$10,592$272.30+$2.00MASDZF
2$377,983,225$375,831,775.70$11,289$357.73+$377.97MASDZF
3$66,433,479,469$66,029,037,418.28$12,123$472.89+$66433.47MASDZF
4$10,916,985,471,987$10,845,901,648,955.73$13,141$629.86+$10916985.46MASDZF
5$1,677,384,363,769,318$1,665,703,189,314,291.80$14,408$846.81+$1677384363.75MASDZF
6$240,985,175,079,139,100$239,190,373,809,905,920.00$16,021$1,151.60+$240985175079.12MASDZF
7$32,373,573,631,143,694,000$32,115,719,493,809,017,000.00$18,122$1,588.22+$32373573631143.68MASDZF
8$4,066,766,648,320,630,000,000$4,032,126,924,535,306,000,000.00$20,930$2,228.20+$4066766648320630.00MASDZF
9$477,730,483,406,513,300,000,000$473,379,043,092,810,300,000,000.00$24,792$3,191.91+$477730483406513344.00MASDZF
10$52,481,917,574,412,750,000,000,000$51,970,745,957,167,775,000,000,000.00$30,274$4,689.40+$52481917574412746752.00MASDZF

ASDZF vs JNJ: Complete Analysis 2026

ASDZFStock

Arctic Star Exploration Corp., a junior natural resource company, acquires, explores for, and develops mineral properties in Canada and Finland. The company primarily explores for diamond and niobium/rare earth deposits. Its flagship project is the Diagras property that consists of 58 contiguous claims with an area of 48,346 hectares located in the north-eastern part of the prolific Lac de Gras kimberlite field. The company also owns 1000% interest in the Timantti diamond project consisting of two exploration permits, which includes the 243 hectares exploration Solavaara Permit and the 882 hectares Vaimouso permit; and 193,700 hectares exploration reservation located in Finland. In addition, it owns 100% interest in the Stein property that consists of four 4 contiguous prospecting permits covering an area of 105,637 hectares located 85 km north-west of Taloyoak. The company was formerly known as Arctic Star Diamond Corp. and changed its name to Arctic Star Exploration Corp. in July 2011. Arctic Star Exploration Corp. was incorporated in 2001 and is headquartered in Vancouver, Canada.

Full ASDZF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ASDZF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ASDZF vs SCHDASDZF vs JEPIASDZF vs OASDZF vs KOASDZF vs MAINASDZF vs ABBVASDZF vs MRKASDZF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.